Stay updated with breaking news from Breakthrough Designation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Plans to have ten or more potentially registrational trials by the end of 2024 Preparing to be commercial-ready by the end of 2025 Ended 2023 with approximately €17.5 billion in cash, cash...
PRINCETON, N.J., Dec. 28, 2023 -- CytoSorbents Corporation , a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its...
CytoSorbents Corporation announced an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board analysis for the...
Designation follows interim Phase 1 PRISM clinical data for 4D-150 that demonstrated an encouraging safety, tolerability and clinical activity profile in patients with wet age-related macular...
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) is aiming to leverage positive study data during 3Q into a Breakthrough Therapy designation from the US...